NeuroOne Medical (NMTC) Prices 16M Share Offering at $0.50/sh

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the pricing of an underwritten registered public offering of 16,000,000 shares of its common stock at a price of $0.50 per share.

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the offering.

All of the shares of common stock to be sold in the offering will be sold by the Company. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 2,400,000 shares of its common stock at the public offering price less the underwriting discount.

The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriter’s option to purchase additional shares, are expected to be $8,000,000. The Company intends to use the net proceeds from this offering for general working capital purposes. The offering is expected to close on or about April 7, 2025, subject to customary closing conditions.

The shares will be issued pursuant to a shelf registration statement on Form S-3 (File No. 333-279871) that was declared effective by the U.S. Securities and Exchange Commission (“SEC”), on August 16, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000 or by email at [email protected].

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

###

You May Also Be Interested In

• ESS Tech launches $3.2M stock offering at $0.50 per share
• Backblaze prices upsized $175M convertible notes due 2031
• Nomadar partners with New Hera to link African athletes to US, Europe